Science and Technology Production
Article
Authorship
Date
2016
Publishing House and Editing Place
LIPPINCOTT WILLIAMS & WILKINS
Magazine
JOURNAL OF THORACIC ONCOLOGY
(pp. 218-219)
LIPPINCOTT WILLIAMS & WILKINS
Summary
Information provided by the agent in
SIGEVA
The CK2 is a Ser/Thr kinase that has been historically associated with cancer. It is involved in cellproliferation, survival and apoptosis by modulating diverse signaling pathways, including Wnt and NF-kBamong the most relevant. CIGB-300 is a synthetic antitumor peptide with a novel mechanism of action, since it is capable of binding to CK2 substrates thus preventing the enzyme activity. NF-kB activation can reducechemotherapy efficiency in lung cancer. We have determined that CIGB-300 inhibits...
The CK2 is a Ser/Thr kinase that has been historically associated with cancer. It is involved in cellproliferation, survival and apoptosis by modulating diverse signaling pathways, including Wnt and NF-kBamong the most relevant. CIGB-300 is a synthetic antitumor peptide with a novel mechanism of action, since it is capable of binding to CK2 substrates thus preventing the enzyme activity. NF-kB activation can reducechemotherapy efficiency in lung cancer. We have determined that CIGB-300 inhibits NF-kB (p65) nucleartranslocation. Based on this evidence, we hypothesize that supplementing cisplatin with CIGB-300 wouldimprove the treatment efficiency. Also, CIGB-300 alters the ability of lung cancer cells to grow in a threedimensional spheroid model.
Show more
Show less
Key Words
CANCERCIGB-300APOPTOSISCK2